ATE503766T1 - Verfahren zur massenherstellung von multimerem mannosebindendem lectin - Google Patents

Verfahren zur massenherstellung von multimerem mannosebindendem lectin

Info

Publication number
ATE503766T1
ATE503766T1 AT04793596T AT04793596T ATE503766T1 AT E503766 T1 ATE503766 T1 AT E503766T1 AT 04793596 T AT04793596 T AT 04793596T AT 04793596 T AT04793596 T AT 04793596T AT E503766 T1 ATE503766 T1 AT E503766T1
Authority
AT
Austria
Prior art keywords
mbl
production
cell line
relates
binding lectin
Prior art date
Application number
AT04793596T
Other languages
English (en)
Inventor
Hong Moon
Jung Yum
Byung Ahn
Joo Lee
Jaeseung Yoon
Original Assignee
Dobeel Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dobeel Co Ltd filed Critical Dobeel Co Ltd
Application granted granted Critical
Publication of ATE503766T1 publication Critical patent/ATE503766T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04793596T 2004-10-28 2004-10-28 Verfahren zur massenherstellung von multimerem mannosebindendem lectin ATE503766T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2004/002739 WO2006046786A1 (en) 2004-10-28 2004-10-28 Method for the mass production of multimeric mannose binding lectin

Publications (1)

Publication Number Publication Date
ATE503766T1 true ATE503766T1 (de) 2011-04-15

Family

ID=36228005

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04793596T ATE503766T1 (de) 2004-10-28 2004-10-28 Verfahren zur massenherstellung von multimerem mannosebindendem lectin

Country Status (10)

Country Link
EP (1) EP1812459B1 (de)
JP (1) JP4592756B2 (de)
AT (1) ATE503766T1 (de)
BR (1) BRPI0419151A (de)
DE (1) DE602004032062D1 (de)
DK (1) DK1812459T3 (de)
ES (1) ES2360504T3 (de)
MX (1) MX2007005107A (de)
PL (1) PL1812459T3 (de)
WO (1) WO2006046786A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
JP5071940B2 (ja) * 2008-12-25 2012-11-14 独立行政法人産業技術総合研究所 抗真菌剤
CA2787376A1 (en) 2010-01-19 2011-07-28 President And Fellows Of Harvard College Engineered opsonin for pathogen detection and treatment
SG10201608671SA (en) 2011-07-18 2016-12-29 Harvard College Engineered Microbe-Targeting Molecules and Uses Thereof
EP2820147B1 (de) 2012-02-29 2018-08-08 President and Fellows of Harvard College Schnelltests auf empfindlichkeit gegen antibiotika
US10551379B2 (en) 2013-03-15 2020-02-04 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
AU2014268603B2 (en) 2013-05-21 2018-03-22 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
EP3546474B1 (de) 2013-12-18 2021-07-07 President and Fellows of Harvard College Crp-erfassung/-detektion von grampositiven bakterien
US10435457B2 (en) 2015-08-06 2019-10-08 President And Fellows Of Harvard College Microbe-binding molecules and uses thereof
WO2022167675A1 (en) 2021-02-08 2022-08-11 Humanitas Mirasole S.P.A. Molecules for use in the treatment and/or prevention of covid-19

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337193B1 (en) * 1998-11-24 2002-01-08 Aptagen, Inc. Expression of manose-binding protein in methylotrophic yeast
US6589534B1 (en) * 1999-09-30 2003-07-08 Yeda Research And Development Co., Ltd. Hepatitis B virus binding proteins and uses thereof
KR100408844B1 (ko) * 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
WO2003010188A1 (en) * 2001-07-23 2003-02-06 Natimmune A/S Production of high molecular mass lectins
WO2003018617A1 (fr) * 2001-08-31 2003-03-06 Fuso Pharmaceutical Industries, Ltd. Procede de purification de lectine liant le mannose humain, compositions de lectine liant le mannose humain et utilisation medicale de la lectine liant le mannose humain
KR100755931B1 (ko) * 2003-06-11 2007-09-06 (주)두비엘 고분자형 만노스 결합형 렉틴의 대량 생산방법 및 상기방법으로 제조된 만노스 결합형 렉틴 재조합 단백질의제제화

Also Published As

Publication number Publication date
ES2360504T3 (es) 2011-06-06
DE602004032062D1 (de) 2011-05-12
EP1812459A4 (de) 2008-10-01
WO2006046786A1 (en) 2006-05-04
EP1812459A1 (de) 2007-08-01
JP2008517619A (ja) 2008-05-29
JP4592756B2 (ja) 2010-12-08
DK1812459T3 (da) 2011-05-23
BRPI0419151A (pt) 2007-12-11
MX2007005107A (es) 2007-09-11
PL1812459T3 (pl) 2011-09-30
EP1812459B1 (de) 2011-03-30

Similar Documents

Publication Publication Date Title
DE60228460D1 (de) Verfahren zur Herstellung und Reinigung von Erythropoietin
ATE503766T1 (de) Verfahren zur massenherstellung von multimerem mannosebindendem lectin
MX2019002345A (es) Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
WO2005112597A3 (en) Transgenic plants expressing intein modified proteins and associated processes for bio-pharmaceutical production
ATE510005T1 (de) Verfahren zur isolierung von zellen aus der nabelschnur
ES2353814T3 (es) Proteinas n-glicosiladas recombinantes de celulas procariotas.
ATE534732T1 (de) Molekulare targets und zusammensetzungen sowie verfahren zu deren identifikation zur behandlung von degenerations- und entzündungserkankungen
UA101155C2 (ru) Модифицированный полипептид фактора vii (fvii) и его применение
EA200800680A1 (ru) Пептидные ингибиторы пути трансдукции сигнала jnk, обладающие способностью проникать в клетку
WO2007110231A3 (en) MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
ECSP088262A (es) Proteínas de fusión de albúmina
DE602006016468D1 (de) Verfahren zur abgabe von fusionspolypeptid in eine zelle
ATE301715T1 (de) Durch molekulares pathogenicid vermittelte krankheitsresistenz in pflanzen
MX2007003906A (es) Metodos y composiciones para mejorar la produccion de proteinas recombinantes.
ATE527349T1 (de) Nervenregeneration
AR071232A1 (es) Proteina hibrida usada como vacuna contra toxinas shiga de e. coli
ATE533838T1 (de) Verfahren zur verbesserten einführung von dna in bakterienzellen
WO2008085962A3 (en) Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants
MY157947A (en) Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
ATE279441T1 (de) Verfahren zur herstellung von genetisch veränderten lymphozyten vorläuferzellen von wirbeltieren und deren gebrauch zur produktion von heterologen bindeproteinen
DE10390418D2 (de) Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
WO2003040681A3 (de) Gene die für stoffwechselweg-proteine codieren
DE69121240D1 (de) T-Zell Lymphoma cDNA Klone
ATE500840T1 (de) Verwendung von gilz-protein zur modulation einer antigenspezifischen immunantwort
DE11151437T1 (de) Genetisch aufbereitetes Gellan

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties